Drug-resistant Candida
Drug-resistant Candida - Related Videos
08:05
Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
0 Views •
Cited by 9 •
2012
We have developed a high-density microarray platform consisting of 3D nano-biofilms of C. albicans called CaBChip. The susceptibility profile of drugs tested on a CaBChip is comparable to the conventional 96-well plate model, suggesting that the fungal chip is ideally suited for true high-throughput screening of antifungal drugs.
08:45
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
0 Views •
Cited by 22 •
2017
This study implemented whole genome sequencing for analysis of mutations in genes conferring antifungal drug resistance in Candida glabrata. C. glabrata isolates resistant to echinocandins, azoles and 5-flucytosine, were sequenced to illustrate the methodology. Susceptibility profiles of the isolates correlated with presence or absence of specific mutation patterns in genes.
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
0 Views •
Cited by 2 •
2015
Drug resistance to targeted therapeutics is widespread and the need to identify mechanisms of resistance--prior to or following clinical onset--is critical for guiding alternative clinical management strategies. Here, we present a protocol to couple derivation of drug-resistant lines in vitro with sequencing to expedite discovery of these mechanisms.
11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
0 Views •
Cited by 4 •
2013
Acquired resistance to antibiotics is a major public healthcare problem and is presently ranked by the WHO as one of the greatest threats to human life. Here we describe the use of cantilever technology to quantify antibacterial resistance, critical to the discovery of novel and powerful agents against multidrug resistant bacteria.
04:17
Dose Escalation: A Method for Developing Drug Resistance in Cancer Cells
0 Views •
2023
The video describes the development of drug resistance in cancer cells by exposing cells to escalating doses of a drug after calculating IC50 values of the drug previously with MTT assay. The sample protocol describes the step-by-step process of developing drug-resistant cells.
FAQs
Target-site mutations can change the cellular structure that an antifungal drug is intended to affect. When the drug no longer binds or acts efficiently at that site, the yeast may continue growing despite treatment. Detecting these genetic changes helps researchers explain reduced drug activity and supports efforts to identify therapies that remain effective against resistant strains.
Drug efflux lowers the amount of antifungal compound retained inside Candida cells, reducing its opportunity to disrupt essential processes. Altered cellular pathways can provide additional ways for the yeast to tolerate drug-related stress. Because these mechanisms affect treatment response differently, studying them helps clarify why a strain withstands one or more drugs.
Biofilm growth creates organized fungal communities in which drug penetration is limited and the cells receive protection from antifungal exposure. This protective setting can make treatment less effective than it would be against more exposed yeast cells. Recognizing biofilm-associated resistance is therefore important when interpreting treatment failure and investigating how resistant communities persist.
Researchers combine susceptibility testing, genomic analysis, and surveillance to characterize resistant Candida. Susceptibility testing evaluates how the strain responds to available antifungal drugs, while genomic analysis can reveal changes associated with resistance. Surveillance tracks resistant strains over time, linking laboratory findings with emerging threats and helping inform treatment selection and infection-control planning.
Resistance testing can help clinicians avoid relying on an antifungal that is unlikely to work against a patient’s strain. This information is particularly relevant for immunocompromised and hospitalized patients, who are identified in the source material as vulnerable groups. Matching therapy to susceptibility findings supports more informed treatment decisions when candidiasis is difficult to manage.
Research findings can guide several responses at once: developing new antifungals, improving diagnostic strategies, strengthening infection-control practices, and refining treatment approaches. Surveillance is especially useful for monitoring emerging resistant strains, while genomic analysis can clarify their characteristics. Together, these activities connect laboratory evidence with clinical and public-health efforts to limit the impact of resistant Candida.